Table 2.

Response and survival data

	Taxane combined platinum-based concurrent chemoradiotherapy
Response at 3 months post radiotherapy*	N = 102
Objective Response	102 (100.0%)
Disease control	102 (100.0%)
Complete response	86 (88.3%)
Partial response	17 (16.7%)
Stable disease	0 (0.0%)
Progressive disease	0 (0.0%)
Response at 6 months post radiotherapy	N = 104
Objective response	104 (100.0%)
Disease control	104 (100.0%)
Complete response	103 (99.0%)
Partial response	1 (1.0%)
Stable disease	0 (0.0%)
Progressive disease	0 (0.0%)

*There was 2 patient who did not undergo radiology examination for tumor response evaluation at 3 months post radiotherapy. Percentage values are rounded